Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597695 · ClinicalTrials.gov registry record · Phase 1
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
A Phase 1 study of Depression, sponsored by Juliana Zambrano, MD, MPH.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06597695: Recruiting Phase 1 study of Depression, sponsored by Juliana Zambrano, MD, MPH.
NCT06597695 is a Phase 1 study of Depression that is actively recruiting participants, run by Juliana Zambrano, MD, MPH. The registered enrollment target is 10 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06597695, a Phase 1 study of Depression, is actively recruiting participants, sponsored by Juliana Zambrano, MD, MPH.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
Conditions Studied
Interventions
- DRUG Ketamine-assisted psychotherapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital, Chelsea - Chelsea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06597695
The ClinicalTrials.gov registry entry for NCT06597695 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The listed sponsor is Juliana Zambrano, MD, MPH, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Ketamine-assisted psychotherapy is the first listed.
NCT06597695 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06597695 about?
NCT06597695 is a clinical study titled "A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression". This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
What is the current status of trial NCT06597695?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-07-23. Estimated completion is 2026-07-01.
What conditions does trial NCT06597695 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06597695?
The interventions under investigation include: Ketamine-assisted psychotherapy (DRUG).
Who is sponsoring clinical trial NCT06597695?
This trial is sponsored by Juliana Zambrano, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06597695 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.